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Resum. Gran part de les qüestions ètiques, legals i morals que 
es deriven del concepte de medicina personalitzada estan pro­
fundament relacionades amb les proves genètiques. En primer 
lloc, hi ha una creixent preocupació sobre la normalització, 
l’exactitud, la utilitat i la interpretació dels resultats que les pro­
ves genètiques directes proporcionen al consumidor. En segon 
lloc, les proves genètiques haurien d’estar restringides per pres­
cripció mèdica i, per tant, hi ha una necessitat urgent de capaci­
tar professionals de salut perquè siguin capaços de proporcio­
nar assessorament genètic específic. En tercer lloc, les proves 
genètiques impliquen una nova dimensió de l’ètica de la privaci­
tat, ja que els resultats obtinguts poden afectar els familiars i, en 
particular, la descendència del pacient. D’altra banda, també 
poden donar lloc a noves formes de discriminació genètica o 
econòmica. Tots aquests factors s’han de tenir en compte per 
tal que les expectatives del públic general respecte a la medicina 
personalitzada siguin més realistes.  
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Summary. Most of the ethical, legal and moral questions that 
result from the concept of personalised medicine are deeply 
related to genetic testing. Firstly, there is an increasing con­
cern about the standardisation, accuracy, usefulness, and in­
terpretation of the results provided by direct­to­consumer 
genetic testing.  Secondly, genetic testing should be restrict­
ed by medical prescription and as such, there is an urgent 
need to train healthcare professionals so that they are also 
able to provide specific genetic counselling. Thirdly, genetic 
testing involves a new dimension of ethics of privacy, be­
cause the results obtained can affect your relatives and in 
particular your offspring. Furthermore, it can also lead to new 
forms of genetic or economic discrimination. All these factors 
should be taken into consideration so that the expectations 
created within the general public with regard to personalised 
medicine are more realistic.
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Most of the ethical, legal and moral questions that result from 
the concept of personalised medicine are deeply related to ge­
netic testing. On the other hands the greatest potential for 
medical advancements in personalised medicine is the devel­
opment of new pharmaceutical drugs for people with a particu­
lar genetic makeup. When addressing the bioethical challenges 
in personalised medicine, we can draw a parallel and learn 
from the ethical debate on direct­to­consumer genetic testing.
Over the past ten years, since the completion of the se­
quencing of the human genome, there has been an explosion 
of websites offering direct­to­consumer genetic testing. As a 
result, there is an increasing concern about the usefulness of 
such tests in providing relevant clinical information for the gen­
eral public. What about the accuracy of genetic testing? What 
standards do we have for their evaluation? Academic scientific 
research laboratories and professional healthcare providers 
only conduct a few, 30 to 35, standardised well­established 
genetic tests. However, we can find at least 2700 genetic tests 
available for purchase online [4]. Moreover, there is a huge var­
iability between results from tests purchased online. Direct­to­
consumer genetic testing has created unrealistic expectations 
that may induce to confusion and anxiety, because in addition 
to this huge variability between the websites or labs offering 
these services, there is a bigger problem related to the inter­
pretation of the results of these tests based on the knowledge 
we have at the moment, and the absence of genetic counsel­
ling, which is not provided by the testing companies.
Most genetic risks claimed in direct­to­consumer genetic 
testing are very uncommon. So, there are genetic risk factors 
that are not relevant in the clinical setting. The products of 
even the most reputable companies (Navigenics, 23andMe, 
deCODE) can show marked differences in the calculated rela­
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tive risk for individuals. Moreover, a genetic risk factor might 
not be the determinant for the development of a particular dis­
ease. We know that there are people with a particular genetic 
risk factor that will never develop the disease while others, 
without this genetic risk factor, may develop the disease due 
to other risk factors, such as environmental factors, occupa­
tional exposures, cholesterol, obesity, etc. If we wish to offer 
patient­tailored treatment planning, we should recognise that 
there is ‘intelligent life’ beyond the genetic tests.
Genetic testing should be restricted by medical prescription 
and as such, there is an urgent need to train healthcare profes­
sionals in genetics, so that they are able to provide specific ge­
netic counselling. This is already the case in many European 
countries. For instance, in France, Germany, Portugal, and 
Switzerland, direct­to­consumer genetic tests are illegal and 
only physicians can carry out genetic tests for medical purpos­
es after providing adequate information to the patients about 
the implications of the finding and their limitations. France, in 
particular, foresees fines of up to €3000 or €4000. Still, the re­
ality is another, because little can be done to stop European 
consumers from purchasing direct­to­consumer genetic test­
ing through websites in the United States, for example, and 
then receiving the results at their own homes.
The third issue that comes out from direct­to­consumer 
genetic testing, particularly relevant in the case of personal­
ised medicine, is related to the privacy and safeguarding of 
our personal and private information. When sending your bio­
logical samples to different online repositories, you run the 
risk of being identified. Genetic testing involves a new dimen­
sion of ethics of privacy, because the results of genetic test­
ing can affect your relatives and in particular your offspring. 
And this is one of the biggest challenges to overcome in per­
sonalised medicine.
Personalised medicine can also lead to new forms of dis­
crimination. For example, certain genotypes are much more 
prevalent in some ethnic groups. Imagine that to recover the 
development costs of a particular drug, pharmaceutical com­
panies targeted the development of new drugs for the most 
prevalent genotypes, and the ones that best respond to treat­
ment. Thus, a large fraction of the world’s population might 
be left out in the development of new treatments, since com­
panies will naturally favour those groups with genotypes that 
hold the potential for more profit. This is a very theoretical 
scenario, but it is something that we should consider. Simi­
larly, insurers or employers could also use ethnic categories 
to lower healthcare costs by discriminating against patient 
groups who are labelled as difficult to treat, based on their 
pharmacogenomic profile. Again, this is a very theoretical 
scenario, but I think it is important to consider these possible 
new forms of genetic discrimination. 
In addition, there is a real risk of economic discrimination. 
The potential profits resulting from genetically tailored drugs 
will probably be reduced because the market is much small­
er, however, pharmaceutical companies will still need to make 
large investments to develop these drugs. Thus, we can pre­
dict that personalised drugs will be more, at least as expen­
sive, if not more, as the standard ones. So who will be able to 
pay for them? Perhaps we should think of the consequences 
of a scenario where only the rich people or the rich countries, 
have the access and can afford the new personalised drugs. 
In my opinion the expectations regarding the clinical rele­
vance of personalised medicine are excessive, have been 
greatly exaggerated and are highly unlikely to be accom­
plished in the short term. 
There are several lobbies behind the topic of personalised 
medicine, scientists, pharmaceutical companies and genetic 
testing labs, which sometimes results in contradictory opin­
ions about the future of personalised medicine. For example, 
some authors think that in contrast to the profusion of genetic 
testing companies, we should expect that the large pharma­
ceutical companies step up their development of personal­
ised drugs very quickly. There are pharmaceutical companies 
that are reluctant to move to this other world where it would 
be more complicated to sell the pharmaceutical drugs to dif­
ferent national health services, compared to when they have 
a ‘blockbuster,’ a one­size­fits­all drug, where you can get a 
lot of revenues, independently of whether this drug works ex­
actly the same in the different populations. This is why some 
authors think that the pharmaceutical industry will be reluc­
tant to adapt immediately to this new world, because that 
would reduce the market size and the associated profits to 
the aforementioned one­size­fits­all drugs. 
To finish, I would like to give you a brief review of state of 
personalised medicine in clinical practice. According to the 
Personalized Medicine Coalition website [2], there were “72 
prominent examples of personalised medicine drugs, treat­
ments and diagnostics products available in 2011.” This is 
simply not true. The US Food and Drug Administration (FDA) 
lists 78 different pharmacogenomic associations that are in­
cluded in drug labels [1], however, more than 60 of these 
drug labels do not provide action­oriented information for 
physicians and patients, and these pharmacogenomic asso­
ciations are for the most part research­based and with no 
clinical use at present. 
As you know, we do not know how to appropriately interpret 
the results from genetic testing, and as such, many genetic 
tests are not relevant for the course of treatment. At present we 
have only a few very good examples in the field of oncology 
where, for instance, particular genetic tests can indicate the 
best course of treatment. 
If we take all this into consideration, the expectations creat­
ed within the general public will be more moderated, and we 
would also reduce the absurd consumption of genetic testing 
in websites that do nothing but can lead to confusion and anxi­
ety. We should help people to better understand and better in­
terpret what really is happening with the new developments 
and breakthroughs in science and how they really work.
In conclusion, I think we should follow the conclusions of a 
2005 report from the British Royal Society entitled Personal­
ised medicines: hopes and realities [3]: “the clinical use of 
personalised medicines where patients are prescribed treat­
ments based on their genetic make­up will not occur for at 
least another 15–20 years.” Or even ten more! In any case, I 
think that personalised medicine is a very good endeavour 
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and that will help us to understand our lives. However, in 
practical terms, we should be very cautious regarding the ex­
pectations and promises of this new mantra.
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